Transarterial Y-90 radioembolization (TARE): Delivery of locally therapeutic radiation via transcatheter arterial injection of Y-90 microparticles into regions of liver
2 radiopharmaceuticals: Y-90 resin microparticles (SirSpheres) and glass microparticles (TheraSpheres)
Concept
Liver malignancies derive ~ 90% of blood supply from hepatic arteries, normal parenchyma 70% from portal vein
Targeted delivery of Y-90 microparticles allows destruction of tumor cells while sparing normal liver
PREPROCEDURE
Indications
Contraindications
Preprocedure Imaging
Getting Started
PROCEDURE
Procedure Steps
POST PROCEDURE
Expected Outcome
Posttherapy Imaging
OUTCOMES
Complications
Selected References
Egger ME et al: Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: A multi-institutional analysis. J Am Coll Surg. 230(4):363-70, 2020
Seraj SM et al: Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease. Am J Nucl Med Mol Imaging. 9(5):248-54, 2019
Uliel L et al: From the angio suite to the γ-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization--a comprehensive pictorial review. J Nucl Med. 53(11):1736-47, 2012
Miller FH et al: Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol. 188(3):776-83, 2007
Related Anatomy
Loading...
Related Differential Diagnoses
Loading...
References
Tables
Tables
KEY FACTS
Terminology
Preprocedure
Procedure
Post Procedure
TERMINOLOGY
Definitions
Transarterial Y-90 radioembolization (TARE): Delivery of locally therapeutic radiation via transcatheter arterial injection of Y-90 microparticles into regions of liver
2 radiopharmaceuticals: Y-90 resin microparticles (SirSpheres) and glass microparticles (TheraSpheres)
Concept
Liver malignancies derive ~ 90% of blood supply from hepatic arteries, normal parenchyma 70% from portal vein
Targeted delivery of Y-90 microparticles allows destruction of tumor cells while sparing normal liver
PREPROCEDURE
Indications
Contraindications
Preprocedure Imaging
Getting Started
PROCEDURE
Procedure Steps
POST PROCEDURE
Expected Outcome
Posttherapy Imaging
OUTCOMES
Complications
Selected References
Egger ME et al: Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: A multi-institutional analysis. J Am Coll Surg. 230(4):363-70, 2020
Seraj SM et al: Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease. Am J Nucl Med Mol Imaging. 9(5):248-54, 2019
Uliel L et al: From the angio suite to the γ-camera: vascular mapping and 99mTc-MAA hepatic perfusion imaging before liver radioembolization--a comprehensive pictorial review. J Nucl Med. 53(11):1736-47, 2012
Miller FH et al: Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol. 188(3):776-83, 2007
STATdx includes over 200,000 searchable images, including x-ray, CT, MR, and ultrasound images. To access all images, please log in or subscribe.